Group One Trading’s Aimmune Therapeutics AIMT Stock Holding History

Group One Trading’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-10,617	Closed	-$180K	–	6452
2020 Q1	$153K	Buy	+10,617	New	+$271K	﹤0.01%	2964
2019 Q4	–	Sell	-9,291	Closed	-$260K	–	5886
2019 Q3	$195K	Buy	9,291 +9,226	+14,194%	+$188K	﹤0.01%	3099
2019 Q2	$1K	Buy	+65	New	+$1.34K	﹤0.01%	4867
2019 Q1	–	Sell	-142	Closed	-$3.34K	–	5642
2018 Q4	$3K	Buy	+142	New	+$3.67K	﹤0.01%	4621
2018 Q2	–	Sell	-17,612	Closed	-$539K	–	5674
2018 Q1	$561K	Buy	+17,612	New	+$620K	0.01%	1967
2017 Q4	–	Sell	-873	Closed	-$28.2K	–	5437
2017 Q3	$22K	Buy	+873	New	+$18.8K	﹤0.01%	4032

Group One Trading's AIMT Position: Q2 2020 in Review

Group One Trading sold out of Aimmune Therapeutics (AIMT) in Q2 2020, closing a stake of 10,617 shares — an estimated $180K sold.

Group One Trading first reported a position in AIMT in Q3 2017 and held it in 6 quarters. The position peaked at $561K in Q1 2018. 165 funds tracked by Wall St. Rank hold AIMT as of Q2 2020.

Group One Trading reported no remaining Aimmune Therapeutics position as of Q2 2020 after selling out during the quarter.
Group One Trading sold 10,617 Aimmune Therapeutics shares in Q2 2020, an estimated $180K.
Group One Trading first reported a position in Aimmune Therapeutics in Q3 2017 and held it in 6 quarters.
Group One Trading's Aimmune Therapeutics position peaked at $561K in Q1 2018.
165 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2020.

Based on Group One Trading's 13F filing for Q2 2020, filed 13 Aug 2020.